Accumulating evidences suggest increased renin-angiotensin-aldosterone system (RAAS)-activity in idiopathic pulmonary arterial hypertension (iPAH). However, the functional consequences of these abnormalities to iPAH pathogenesis remains obscure.
Accumulating evidences suggest increased renin-angiotensin-aldosterone system (RAAS)-activity in idiopathic pulmonary arterial hypertension (iPAH). However, the functional consequences of these abnormalities to iPAH pathogenesis remains obscure.
What This Study Adds to the Field
In this translational study we have demonstrated that: 1) Systemic RAAS activation is increased in iPAH patients and associated with worse prognosis;
2) Due to the increased ACE-activity, pulmonary endothelial cells of iPAH-patients produces more angiotensin II, which induces significant pulmonary artery smooth muscle cell proliferation of iPAHpatients via AT 1 -receptor signalling;
3) AT 1 -receptor expression and signalling is upregulated in iPAH-patients, without changes in AT 2 -receptor expression; 
INTRODUCTION
Idiopathic pulmonary arterial hypertension (iPAH) is a fatal disease with an average mortality rate of 58% within 3 years after diagnosis.(1) The disease is characterized by excessive pulmonary vascular remodeling, leading to elevated pressures in the pulmonary arterial system and the right heart.(2) As a consequence, iPAH-patients often have a low cardiac output. (2) To compensate, neurohormonal systems like renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) are upregulated but this may have long-term negative effects on the progression of iPAH. (3) In contrast to the increasing knowledge on the role of altered SNS signaling in the development of iPAH,(4-7) only little is known about alterations in RAAS signaling in iPAH. Two different polymorphisms in the angiotensin II type 1 (AT 1 ) receptor and angiotensin converting enzyme (ACE) are associated with disease progression and age-at-diagnosis in iPAH-patients. (8, 9) In addition, increased expression of pulmonary vascular ACE has been observed in patients with primary and secondary plexiform pulmonary hypertension.(10) Nevertheless, it is still unclear whether systemic and local RAAS-activity is associated with disease progression and pulmonary vascular remodeling. Recently, the discovery of angiotensin converting enzyme 2 (ACE2) lead to renewed interest in the RAAS-signaling in PAH. (14, 15) ACE2 functions as a carboxypeptidase and cleaves a single carboxylate-terminal residue from AngII to form Ang (1) (2) (3) (4) (5) (6) (7) . (16) The goal of this study was: 1) To determine whether RAAS-activity is increased in iPAH-patients, both systemically in serum and locally in pulmonary arteries (PA) and pulmonary endothelial cells (P-EC) of iPAH-patients and controls; 2) To investigate whether local RAAS-activity could induce proliferation of human cultured pulmonary artery smooth muscle cell (PA-SMC) derived from iPAH-patients and controls; 3) To elucidate the therapeutic potential of RAAS, by evaluating the effects of chronic AT 1 -receptor inhibition in an experimental PAH model.
Some of the results of this study have been previously reported in the form of an abstract. (17, 18) 
Part II -Local RAAS-activity in pulmonary vasculature of iPAH-patients
This part of the study was approved by the local ethics committee of the CPP Ile-de France VII, Le Kremlin-Bicêtre (France). All patients gave informed consent before the study. Lung specimens were obtained during lung transplantation (iPAH, n=13) and during lobectomy or pneumonectomy for cancer (controls, n=14). In controls, pulmonary cells were isolated distant from tumor areas.
Pulmonary arteries (PA), P-ECs and PA-SMCs of iPAH-patients and controls were isolated, as described before. (19, 20) PAs were used for protein analyses of AT 1 -receptor, AT 2 -receptor expression, SRC-and ERK-activation. Localization of AT 1 -receptor, AngII production by P-ECs and PA-SMC proliferation after exposure of AngII were assessed as described in the Online Data Supplement.
Part III -Effects of chronic AT 1 -receptor inhibition in experimental PAH
All animal experiments were approved by the Institutional Animal Care and Use Committee of the VU University Amsterdam (the Netherlands).
Prior to the efficacy study, we performed a dose-finding study to determine the maximum tolerated dose of losartan, as described before.(5) The maximum tolerated dose was defined as less than 10% reduction in systemic blood pressure. 6 Subsequently, efficacy of chronic losartan treatment was tested in 27 rats (no telemetry): 9 control and 18 PAH-rats (monocrotaline 60 mg/kg). Ten days after monocrotaline-injection (when rats have developed PAH),(5) PAH-rats were randomized for losartan treatment (20 mg/kg dissolved in vanilla pudding) or vehicle (vanilla pudding) once daily (n=9/group). Rats were treated for maximal 25 days.
For hemodynamic assessment, longitudinal echocardiography and pressure-volume analyses were performed. (5, 21) To determine morphological changes in heart and lungs, RV hypertrophy and muscularization of pulmonary arterioles were assessed.(5, 21)
Statistical analyses
All data were verified for normal distribution and log transformed when necessary. Data are presented as mean±SEM, unless stated otherwise. A p-value of p<0.05 was considered statistically significant. Comparisons of serum renin, AngI and AngII with their upper limit of normal reference values were performed by one-sample t-test. Prognostic relevance of serum renin, AngI and AngII was determined by univariate Cox-regression analyses and subsequent correction for confounding effects of gender, age and time-to-diagnosis. All-cause mortality and lung transplantation was recorded as an event in the Cox-regression analyses. Subgroup analyses of serum follow-up measurements were performed by 2-way ANOVA for repeated measurements. AT 1 -receptor expression and activity was analyzed by unpaired t-test. P-EC AngII production, PA-SMC proliferation, the effects of losartan on disease progression and pressure-volume analyses were analyzed by oneway ANOVA with bonferroni post-hoc analyses. Histological data were analyzed using multilevel Table 1 .
Serum levels of renin-activity, AngI and AngII were significantly increased in comparison to the upper-limit of normal (dotted line; Fig.1A-C) . In addition, increased AngII and renin-activity were significantly associated with an increase risk of death or lung transplantation, even after correction for age, gender and time-to-diagnosis (Table 3 ).
Subgroup analyses of the 21 patients with follow-up measurements of serum RAAS revealed that renin-activity, AngI and AngII serum levels were associated with worsening of iPAH. For this purpose, we divided patients in two groups: stable iPAH-patients with <10% decrease in 6MWD and progressive iPAH-patients with >10% decrease in 6MWD. Renin-activity, AngI and AngII serum levels were unaltered in stable iPAH-patients, whereas they were significantly increased over time in progressive iPAH-patients ( Fig.1D-F ).
These findings indicate that systemic RAAS-activity is elevated and associated with disease progression and mortality.
Part II -Local RAAS-activity in pulmonary vasculature of iPAH-patients

Increased AngII production via elevated ACE-activity in pulmonary endothelial cells of iPAH-patients
To investigate whether RAAS-activity is also locally upregulated in the pulmonary vasculature of iPAH-patients, we isolated P-ECs of lung specimens of iPAH-patients and control subjects. We measured AngII levels in media of isolated P-ECs of iPAH-patients and controls with and without exposure to AngI. Both in controls and iPAH-patients, AngI exposure induced an increase in AngII production. However, P-ECs of iPAH-patients produced significantly more AngII after AngI exposure than P-ECs of control subjects (p<0.01; Fig.2 ). Conversion of AngI to AngII is regulated via ACE. To investigate whether the increased AngII production in P-ECs of iPAH-patients is caused by elevated 8 ACE-activity, we subsequently exposed P-ECs of iPAH-patients and controls to AngI in combination with the ACE inhibitor enalapril. Interestingly, co-incubation with enalapril totally abolished the observed difference in AngII production between P-ECs of iPAH-patients and control subjects (p<0.001; Fig.2 ). This indicates that P-ECs of iPAH-patients produce significantly more AngII upon AngI incubation via elevated ACE-activity.
Elevated expression and signaling of the AT 1 -receptor in pulmonary arteries of iPAH-patients
AngII has binding affinity for two receptors: the AT 1 -receptor and the AT 2 -receptor. (24) To investigate whether protein levels of AngII receptors are altered in the pulmonary vasculature of iPAH-patients, we performed immunohistochemical localization of proteins in situ and Western blot analysis of lung specimens from iPAH-patients and controls. Intrestingly, we found a marked increased AT 1 -receptor within walls of distal pulmonary arteries from iPAH-patients as shown by immunohistology (Fig. 3A) .
Consistent with these in situ findings, Western blot analyses of the AT 1 -and AT 2 -receptor, revealed a more than two fold increase in expression of AT 1 -receptor (Fig.3B) . To test whether the observed elevation in AT 1 -receptor expression also resulted in increased receptor signaling, we measured the activity of downstream targets of AT 1 -receptor, the tyrosine kinase SRC and extracellular regulated kinase (ERK). As can be observed in Fig.3C , SRC-and ERK-activity were significantly increased in iPAHpatients in comparison to controls. These findings indicate that in iPAH-patients the AT 1 -receptor expression and signaling are increased.
AngII induces proliferation of pulmonary artery smooth muscle cells of iPAH-patients via AT 1 -receptor signaling
To investigate whether AngII induce PA-SMC proliferation, we isolated and cultured PA-SMCs of iPAH-patients and controls. Incubation with 10% fetal calf serum confirmed the previously found proproliferative state of iPAH PA-SMCs. (19) AngII incubation induced specific proliferation of the PASMCs of iPAH-patients, while no change in proliferation of control PA-SMCs was observed (Fig.4) . To 
Part III -Effects of chronic AT 1 -receptor inhibition in experimental PAH
To investigate whether chronic inhibition of AT 1 -receptor signaling could have therapeutic potential for the treatment of PAH, we performed a pre-clinical study in a well-established rat-model with PAH induced by high dose of monocrotaline. (21) First, we performed a dose-finding study to determine the maximum tolerated dose of losartan, which was defined as less than 10% reduction in systemic blood pressure ( 
Losartan reduces pulmonary vascular remodeling in PAH-rats
Ten days after injection, echocardiographic analyses revealed clear signs of PAH in all monocrotalinetreated rats. Estimated right ventricular (RV) systolic pressures (PAAT/cl and eRVSP) and pulmonary vascular remodeling (PVR) were significantly increased in comparison to controls, and early signs of RV hypertrophy and dilatation were observed in all 18 PAH-rats (Table E1 ).
Serial echocardiography (at day 10 and at end-of-study) demonstrated a significantly delayed disease progression in losartan treated rats (Fig.6 ). The increment in pulmonary vascular remodeling was reduced in losartan treated PAH-rats in comparison to vehicle-treated PAH-rats ( Fig. 6A 
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DISCUSSION
To the best of our knowledge, this is the first study to demonstrate the effects of increased systemic and local RAAS-activity in iPAH-patients. Using a translational approach wit a set of physiological and pathological endpoints, we have demonstrated that:
1. Systemic RAAS-activity is increased in iPAH-patients and associated with disease progression and the risk of death or lung transplantation.
2. Due to increased ACE-activity, pulmonary endothelial cells of iPAH-patients produces more angII, which induces significant pulmonary artery smooth muscle cell proliferation of iPAHpatients via AT 1 -receptor signaling; 
Elevated systemic and local RAAS-activity
RAAS-activity is regulated systemically and locally in a variety of tissues (brain, skin, digestive organs, lymphatic tissue, adipose tissue, vasculature and heart).(25) Systemic RAAS-activity is mainly controlled via the release of renin, secreted by the juxtaglomerular cells of the kidney, cleaving angiotensinogen into AngI, which is subsequently cleaved by ACE to form AngII. (26) In left heart failure, the prognostic importance of increased systemic RAAS-activity has been recognized for a long time. (27) In PAH, it as suggested that systemic RAAS-activity was upregulated, based on the findings of upregulated SNS-activity (4-7) and the prognostic importance of hyponatremia.(28) However, Whether the systemic changes in RAAS-activity override the local changes in the lungs is unclear.
However, it is expected that increased systemic RAAS-activity would further exaggerate the local 13 changes in RAAS-activity in the lungs. In our study, we used similar concentrations of AngI for both PAH-patients and controls, whereas in reality P-ECs of iPAH-patients are exposed to even higher AngI concentrations. The observed changes in local RAAS-activity may therefore even be underestimated.
Therapeutic potential of RAAS
In the nineties, two small case series testing the short-term effectiveness of ACE-inhibitors in iPAH- Mixed effects of AT 1 -receptor antagonist on cardiac function were observed in our pre-clinical model:
we found no changes in stroke volume/cardiac output and RV hypertrophy, but reduced RV dilatation and diastolic elastance. It can be speculated that chronic AT 1 -receptor blockade exerts pulmonary effects rather than cardiac effects. The changes in RV dilatation and diastolic elastance would then be a mere consequence of reduced RV afterload due to reduced pulmonary vascular remodeling. Nevertheless, then still a reduction in RV wall thickness would be expected. Probably, Furthermore, although losartan was able to reduce RV afterload, RV afterload was not normalized.
We hypothesize that the reduction in RV afterload was only sufficient to exert partial normalization of RV function and morphology. We did similar observations in clinical PAH,(37) where reduction in PVR not always translated into improvement in RV ejection fraction.
Limitations
In this study, we only used patient samples with iPAH to prevent confounding effects of other comorbidities as for instance inflammation in scleroderma-associated PAH. Based on the previous finding of increased sympathetic system activity in PAH and the close association between sympathetic system and RAAS activity, we would suspect that systemic and local RAAS-activation are also increased in other forms of PAH. However, at this point we cannot conclude this with firm certainty.
To assess AT 1 -receptor activity, we measured activity of the tyrosine kinase SRC and ERK. However, other upstream pathways could also affect phosphorylation of these kinases. Nevertheless, the abolishing effect of AT 1 -receptor antagonist on PA-SMC proliferation, indicates that increased AT 1 -receptor activity is important in the pathophysiology of iPAH.
In our study we could not observe a significant reduction in AT 2 -receptor expression in pulmonary arteries. This may be due to a low power of the analyses. Although, the difference between control and iPAH is small, we cannot exclude that reduced AT 2 -receptor expression could further exaggerate the proliterative effects on PA-SMCs. However, this further underlines the importance of selective AT 1 -receptor blockers, since ACE-inhibitors would affect both AT 1 as well as AT 2 -receptor expression.
Our pressure-volume analyses do not allow us to determine whether treatment has altered diastolic and systolic volumes. However, in combination with our echocardiographic derived RV end-diastolic -blocker 3 Simvastatin 1 Data presented as mean±SD. NYHA, New York Heart Association class; 6MWD, six minute walk distance; NT-proBNP, N-terminal pro brain natriuretic peptide; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CO, cardiac output; HR, heart rate; RAP, right atrial pressure; PCWP, pulmonary capillary wedge pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate. Loasartan reduced RV arterial elastance (D) without affecting RV contractility (E). In addition, RV diastolic function improved significantly after losartan treatment illustrated by reduced RV enddiastolic elastance (F). For measurements of RV dilatation, see Figure 6 .
Data presented as mean ±SEM, n=9 per group. Con, control; PAH, pulmonary arterial hypertension. 
Laboratory analyses
Renin activity (n=79 samples) was determined using the Renin III generation assay kit (Cisbio, Codolet, France). This assay consists of a pair of antibodies: first monoclonal antibody recognizes both the active and inactive form of renin, second monoclonal antibody specifically recognizes the active form of renin. In addition, serum levels of Ang I (n=73 samples) by a home-brew radioimmunometric assay (IJssellandziekenhuis) and Ang II (n=79 samples) by using a radioimmunoassay kit (RB320, Euro-diagnostica, Malmö, Sweden).
Part II -Local RAAS activity in pulmonary vasculature of iPAH-patients
Measurement of Ang II production by P-ECs
Medium of P-EC was used to measure Ang II levels upon Ang I incubation. For this purpose, medium was obtained from serum-starved P-ECs in MCDB 131 medium (0% FCS) for 24 hours with or without USA) by SDS-PAGE, as previously described. E2 Protein levels were corrected for differences in protein loading by β-actin (1:5000; A5316, Sigma-Aldrich, St. Louis, USA).
For the localization of the AT 1 -receptor expression, paraffin-embedded sections were incubated overnight at 4°C with primary AT 1 -receptor antibody (1:100; sc-1173, Santa Cruz Biotechnology, Santa Cruz, USA), as previously described.
E2
Part III -Beneficial effects of chronic AT 1 -receptor inhibition in experimental PAH
Nine rats were equipped with an implantable telemetric pressure-transmitter placed in the abdominal aorta as previously described. E3 First, baseline aortic pressures were measured over 3 consecutive days. Subsequently, different dosages of losartan dissolved in vanilla pudding were administered for 3 consecutive days: 2 rats received 40 mg/kg losartan, 2 rats received 20 mg/kg losartan, 3 rats received 10 mg/kg losartan and 2 rats received 5 mg/kg losartan. After dose-finding in control rats, we induced pulmonary hypertension by a single injection of a high dose of monocrotaline (MCT 60 mg/kg). Two weeks after the MCT-injection, PAH was developed and we repeated baseline measurements for 2 consecutive days in the PAH rats. Subsequently, different 
Assessment of disease progression by longitudinal echocardiography after losartan
Rats were evaluated by echocardiography 10 days after (monocrotaline-)injection and at end-ofstudy (when manifest right heart failure developed, or 35 days after injection). When rats developed clinical signs of manifest right heart failure (defined as >10% loss in body mass and/or respiratory distress, cyanosis, lethargy) were euthanized earlier, in keeping with the protocol of the local animal care and use committee. E3-7 Transthoracic echocardiographic measurements (ProSound SSD-4000 system equipped with a 13-MHz linear transducer (UST-5542), Aloka, Tokyo, Japan) were performed on anesthetized but spontaneously breathing rats (isoflurane 2.0% 
